TEVA-CLONIDINE TABLET

Land: Canada

Sprog: engelsk

Kilde: Health Canada

Aktiv bestanddel:

CLONIDINE HYDROCHLORIDE

Tilgængelig fra:

TEVA CANADA LIMITED

ATC-kode:

C02AC01

INN (International Name):

CLONIDINE

Dosering:

0.2MG

Lægemiddelform:

TABLET

Sammensætning:

CLONIDINE HYDROCHLORIDE 0.2MG

Indgivelsesvej:

ORAL

Enheder i pakken:

100/500

Recept type:

Prescription

Terapeutisk område:

CENTRAL ALPHA-AGONISTS

Produkt oversigt:

Active ingredient group (AIG) number: 0108891002; AHFS:

Autorisation status:

APPROVED

Autorisation dato:

2013-12-13

Produktets egenskaber

1
PRODUCT MONOGRAPH
PR
TEVA-CLONIDINE
(Clonidine Hydrochloride)
0.1 mg and 0.2 mg Tablets
USP
Antihypertensive
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
M1B 2K9
Submission Control No: 171843
Date of Revision:
April 25, 2014
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY
PRODUCT
INFORMATION
................................................................................
3
INDICATIONS
AND
CLINICAL
USE
......................................................................................
3
CONTRAINDICATIONS
...........................................................................................................
3
WARNINGS
AND
PRECAUTIONS
.........................................................................................
4
ADVERSE
REACTIONS
...........................................................................................................
7
DRUG
INTERACTIONS
............................................................................................................
9
DOSAGE
AND
ADMINISTRATION
......................................................................................
11
OVERDOSAGE
........................................................................................................................
12
ACTION
AND
CLINICAL
PHARMACOLOGY
....................................................................
13
STORAGE
AND
STABILITY
.................................................................................................
14
DOSAGE
FORMS,
COMPOSITION
AND
PACKAGING ..................................................... 14
PART II: SCIENTIFIC INFORMATION
...............................................................................
16
PHARMACEUTICAL
INFORMATION
.................................................................................
16
DETAILED
PHARMACOLOGY
............................................................................................
17
TOXICOLOGY
...........................